Who are Kiniksa's investors?

Kiniksa's investors include Sofinnova Ventures, Deerfield Management Company, Sofinnova Venture Partners.

How much funding has Kiniksa raised?

Kiniksa has disclosed $276.9M raised across 4 rounds.

Where is Kiniksa headquartered?

Kiniksa is headquartered in Hamilton.

Kiniksa

NASDAQ: KNSA

Hamilton · Founded 2015 · 412 employees on LinkedIn · 3 known investors

Find your way into Kiniksa

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions. The company has an FDA-approved therapy and multiple clinical-stage assets in its pipeline.

Biotech Medical Devices

Founders & leadership

Sanj K. PatelChief Executive Officer and Chairman of the Board

RICHARD S LEVYNamed on SEC filing

STEPHEN R BIGGARNamed on SEC filing

FELIX J BAKERNamed on SEC filing

THOMAS W BEETHAMNamed on SEC filing

THOMAS R MALLEYNamed on SEC filing

G. BRADLY COLENamed on SEC filing

BARRY D QUARTNamed on SEC filing

KIMBERLY J POPOVITSNamed on SEC filing

TRACEY L MCCAINNamed on SEC filing

Investors · 3

Sofinnova VenturesMenlo Park · $100K – $15M

Deerfield Management CompanyreportedNew York

Sofinnova Venture PartnersreportedMenlo Park

Reported raises · per SEC filings

Form D private placements

$276.9M disclosed across 4 rounds · 2015–2019

▶$8.8MraisedNov 2020 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

RICHARD S LEVYDirector
STEPHEN R BIGGARDirector
FELIX J BAKERDirector
THOMAS W BEETHAMExecutive Officer
SANJ K PATELExecutive Officer, Director
THOMAS R MALLEYDirector
G. BRADLY COLEDirector
BARRY D QUARTDirector
KIMBERLY J POPOVITSDirector
TRACEY L MCCAINDirector

Offering amount: $8.8M
Amount sold: $8.8M
First sale: Mar 2019
Incorporated: Corporation, Bermuda, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$336.9Mvaluation at IPOFeb 2019 · $18.26/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 1

by search overlap

Medscape24 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Kiniksa for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Precision Wealth Strategies LLC Buys Shares of 14,063 Kiniksa Pharmaceuticals International, plc $KNSA - Markets Dailythemarketsdaily.com · Jul 2026

Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 4.7% -- What GF Score of 50 Tells Investorsgurufocus.com · Jul 2026

Here's Why You Should Add Kiniksa Stock to Your Portfolio Nowfinance.yahoo.com · Jun 2026

Kiniksa's ARCALYST Sales Soar 56%, Funding a Next-Gen Heart Drug Pipeline - BriefGlance.combriefglance.com · Apr 2026

Frequently asked questions

What does Kiniksa do?: Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions. The company has an FDA-approved therapy and multiple clinical-stage assets in its pipeline.
Who are Kiniksa's investors?: Kiniksa's investors include Sofinnova Ventures, Deerfield Management Company, Sofinnova Venture Partners.
How much funding has Kiniksa raised?: Kiniksa has disclosed $276.9M raised across 4 rounds.
Where is Kiniksa headquartered?: Kiniksa is headquartered in Hamilton.